P Lucato1, C Trevisan1, B Stubbs2,3, B M Zanforlini1, M Solmi4,5, C Luchini6,7, G Girotti1, S Pizzato1, E Manzato1,8, G Sergi1, S Giannini9, M Fusaro10, N Veronese11,12. 1. Department of Medicine - DIMED, Geriatrics Division, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy. 2. Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, SE5 8AZ, UK. 3. Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, De Crespigny Park, Box, SE5 8 AF, London, UK. 4. Department of Neurosciences, University of Padova, Padova, Italy. 5. Institute of Clinical Research and Education in Medicine (IREM), Padova, Italy. 6. Department of Pathology and Diagnostics, Verona University and Hospital Trust, Verona, Italy. 7. Azienda Provinciale per i Servizi Sanitari (APSS) Trento, Trento, Italy. 8. National Research Council, Aging Branch, Institute of Neuroscience, Padova, Italy. 9. Department of Medicine, Clinica Medica I, University of Padova, Padova, Italy. 10. National Research Council (CNR), Neuroscience Institute, Padova, Italy. 11. Department of Medicine - DIMED, Geriatrics Division, University of Padova, Via Giustiniani, 2, 35128, Padova, Italy. ilmannato@gmail.com. 12. Institute of Clinical Research and Education in Medicine (IREM), Padova, Italy. ilmannato@gmail.com.
Abstract
Our meta-analysis demonstrates that people with nephrolithiasis have decreased bone mineral density, an increased odds of osteoporosis, and potentially an elevated risk of fractures. INTRODUCTION: People with nephrolithiasis might be at risk of reduced bone mineral density (BMD) and fractures, but the data is equivocal. We conducted a meta-analysis to investigate if patients with nephrolithiasis have worse bone health outcomes (BMD), osteoporosis, and fractures versus healthy controls (HCs). METHODS: Two investigators searched major databases for articles reporting BMD (expressed as g/cm2 or a T- or Z-score), osteoporosis or fractures in a sample of people with nephrolithiasis, and HCs. Standardized mean differences (SMDs), 95 % confidence intervals (CIs) were calculated for BMD parameters; in addition odds (ORs) for case-control and adjusted hazard ratios (HRs) in longitudinal studies for categorical variables were calculated. RESULTS: From 1816 initial hits, 28 studies were included. A meta-analysis of case-control studies including 1595 patients with nephrolithiasis (mean age 41.1 years) versus 3402 HCs (mean age 40.2 years) was conducted. Patients with nephrolithiasis showed significant lower T-scores values for the spine (seven studies; SMD = -0.69; 95 % CI = -0.86 to -0.52; I 2 = 0 %), total hip (seven studies; SMD = -0.82; 95 % CI = -1.11 to -0.52; I 2 = 72 %), and femoral neck (six studies; SMD = -0.67; 95 % CI = --1.00 to -0.34; I 2 = 69 %). A meta-analysis of the case-controlled studies suggests that people with nephrolithiasis are at increased risk of fractures (OR = 1.15, 95 % CI = 1.12-1.17, p < 0.0001, studies = 4), while the risk of fractures in two longitudinal studies demonstrated trend level significance (HR = 1.31, 95 % CI = 0.95-1.62). People with nephrolithiasis were four times more likely to have osteoporosis than HCs (OR = 4.12, p < 0.0001). CONCLUSIONS: Nephrolithiasis is associated with lower BMD, an increased risk of osteoporosis, and possibly, fractures. Future screening/preventative interventions targeting bone health might be indicated.
Our meta-analysis demonstrates that people with nephrolithiasis have decreased bone mineral density, an increased odds of osteoporosis, and potentially an elevated risk of fractures. INTRODUCTION:People with nephrolithiasis might be at risk of reduced bone mineral density (BMD) and fractures, but the data is equivocal. We conducted a meta-analysis to investigate if patients with nephrolithiasis have worse bone health outcomes (BMD), osteoporosis, and fractures versus healthy controls (HCs). METHODS: Two investigators searched major databases for articles reporting BMD (expressed as g/cm2 or a T- or Z-score), osteoporosis or fractures in a sample of people with nephrolithiasis, and HCs. Standardized mean differences (SMDs), 95 % confidence intervals (CIs) were calculated for BMD parameters; in addition odds (ORs) for case-control and adjusted hazard ratios (HRs) in longitudinal studies for categorical variables were calculated. RESULTS: From 1816 initial hits, 28 studies were included. A meta-analysis of case-control studies including 1595 patients with nephrolithiasis (mean age 41.1 years) versus 3402 HCs (mean age 40.2 years) was conducted. Patients with nephrolithiasis showed significant lower T-scores values for the spine (seven studies; SMD = -0.69; 95 % CI = -0.86 to -0.52; I 2 = 0 %), total hip (seven studies; SMD = -0.82; 95 % CI = -1.11 to -0.52; I 2 = 72 %), and femoral neck (six studies; SMD = -0.67; 95 % CI = --1.00 to -0.34; I 2 = 69 %). A meta-analysis of the case-controlled studies suggests that people with nephrolithiasis are at increased risk of fractures (OR = 1.15, 95 % CI = 1.12-1.17, p < 0.0001, studies = 4), while the risk of fractures in two longitudinal studies demonstrated trend level significance (HR = 1.31, 95 % CI = 0.95-1.62). People with nephrolithiasis were four times more likely to have osteoporosis than HCs (OR = 4.12, p < 0.0001). CONCLUSIONS:Nephrolithiasis is associated with lower BMD, an increased risk of osteoporosis, and possibly, fractures. Future screening/preventative interventions targeting bone health might be indicated.
Entities:
Keywords:
Bone mineral density; Fractures; Kidney stone; Nephrolithiasis; Osteoporosis
Authors: John R Asplin; Kimberly A Bauer; Jennifer Kinder; Georg Müller; Brian J Coe; Joan H Parks; Fredric L Coe Journal: Kidney Int Date: 2003-02 Impact factor: 10.612
Authors: M Fuss; T Pepersack; J Van Geel; J Corvilain; J C Vandewalle; P Bergmann; J Simon Journal: Calcif Tissue Int Date: 1990-01 Impact factor: 4.333
Authors: A Ghazali; V Fuentès; C Desaint; P Bataille; A Westeel; M Brazier; L Prin; A Fournier Journal: J Clin Endocrinol Metab Date: 1997-01 Impact factor: 5.958
Authors: Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin; Salvador Arias-Santiago; Juan Garrido-Gomez; Tomas De De Haro-Muñoz; Armando Zuluaga-Gomez Journal: Singapore Med J Date: 2012-12 Impact factor: 1.858
Authors: Enrique Diaz-Convalia; Miguel Angel Arrabal-Polo; Maria Del Carmen Cano-Garcia; Alejandro Dominguez-Amillo; Nelson Canales-Casco; Miguel Arrabal-Martin Journal: Int Urol Nephrol Date: 2018-01-27 Impact factor: 2.370
Authors: Nasser A Dhayat; Lisa Schneider; Albrecht W Popp; David Lüthi; Cedric Mattmann; Bruno Vogt; Daniel G Fuster Journal: Kidney Int Rep Date: 2021-12-15